PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-25.41%
Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.
610.74%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
609.26%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
609.26%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth above 1.5x AXSM's 25.25%. David Dodd would confirm a clear edge in underlying cash generation.
320.27%
FCF growth above 1.5x AXSM's 25.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
419.54%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
400.10%
3Y OCF/share CAGR above 1.5x AXSM's 23.58%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
706.07%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
706.07%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
315.93%
3Y net income/share CAGR above 1.5x AXSM's 11.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-251.89%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-251.89%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-24.04%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
50-75% of AXSM's 35.76%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-14.44%
We’re deleveraging while AXSM stands at 2.81%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.